Trial Profile
A Comparison of LY2605541 Versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naive Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With 2 or More Oral Antihyperglycemic Medications: An Open-Label, Randomized Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin peglispro (Primary) ; Insulin suspension isophane (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms IMAGINE-6
- Sponsors Eli Lilly and Company
- 09 Jun 2015 Results (pooled analysis of IMAGINE 1, 2, 3, 4, 5 and 6 trials) presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 06 Jun 2015 According to an Eli Lilly media release, results of this study were presented at the 75th American Diabetes Association's Scientific Session 2015.